Oncology players in the red on Celgene deal

|By:, SA News Editor

A wide range of oncology companies are under modest pressure after deal-hungry Bristol-Myers Squibb announced its $74B bid for Celgene, thereby removing a top candidate from the list of potential suitors.

Selected tickers: (NLNK -9%)(CRVS -9.4%)(NKTR -6.8%)(BLCM -4.8%)(CLDX -4.8%)(AFMD -2.2%)(JNCE -4.1%)(EDIT -3.4%)(LOXO -3.8%)(FPRX -3.6%)(LABU -5.8%)(BPMC -4%)(PBYI -4.5%)(CLLS -2%)(CYCC -1.9%)(BLUE -1.8%)

Previously: Bristol-Myers Squibb to acquire Celgene for $74B (Jan. 3)

Subscribe for full text news in your inbox